| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 分部间抵销(元) | - | - | -10,125,940.66 | - | -15,549,614.47 |
| 医药制造业务(元) | - | - | 831,842,219.71 | - | 783,315,942.27 |
| 儿科(元) | - | 182,874,123.88 | - | 188,169,688.60 | - |
| 妇科(元) | - | 81,338,912.79 | - | 92,369,573.94 | - |
| 骨伤科(元) | - | 384,152,869.84 | - | 358,927,489.58 | - |
| 呼吸系统用药(元) | - | 213,495,651.46 | - | 179,609,459.87 | - |
| 抗感染(元) | - | 77,698,100.45 | - | 81,854,461.84 | - |
| 心脑血管(元) | - | 530,494,346.50 | - | 384,553,335.27 | - |
| 提供服务(元) | 44,911,160.14 | - | - | - | - |
| 销售商品(元) | 789,337,815.49 | - | - | - | - |
| 其他(元) | - | 239,746,888.98 | 61,893,700.28 | 283,965,368.71 | 63,398,219.98 |
| 营业成本(元) | |||||
| 分部间抵销(元) | - | - | -17,353,686.47 | - | -20,959,703.54 |
| 医药制造业务(元) | - | - | 210,170,807.42 | - | 226,643,546.89 |
| 儿科(元) | - | 61,610,907.41 | - | 65,674,949.83 | - |
| 妇科(元) | - | 17,436,974.51 | - | 19,158,533.85 | - |
| 骨伤科(元) | - | 65,569,496.71 | - | 52,382,093.23 | - |
| 呼吸系统用药(元) | - | 50,260,934.38 | - | 49,482,187.26 | - |
| 抗感染(元) | - | 47,028,051.02 | - | 52,951,072.53 | - |
| 心脑血管(元) | - | 102,362,522.02 | - | 100,102,496.04 | - |
| 提供服务(元) | 39,664,702.60 | - | - | - | - |
| 销售商品(元) | 208,126,288.08 | - | - | - | - |
| 其他(元) | - | 126,356,857.49 | 47,633,126.83 | 145,281,251.56 | 47,042,636.00 |
| 毛利(元) | |||||
| 分部间抵销(元) | - | - | 7,227,745.81 | - | 5,410,089.07 |
| 医药制造业务(元) | - | - | 621,671,412.29 | - | 556,672,395.38 |
| 儿科(元) | - | 121,263,216.47 | - | 122,494,738.77 | - |
| 妇科(元) | - | 63,901,938.28 | - | 73,211,040.09 | - |
| 骨伤科(元) | - | 318,583,373.13 | - | 306,545,396.35 | - |
| 呼吸系统用药(元) | - | 163,234,717.08 | - | 130,127,272.61 | - |
| 抗感染(元) | - | 30,670,049.43 | - | 28,903,389.31 | - |
| 心脑血管(元) | - | 428,131,824.48 | - | 284,450,839.23 | - |
| 提供服务(元) | 5,246,457.54 | - | - | - | - |
| 销售商品(元) | 581,211,527.41 | - | - | - | - |
| 其他(元) | - | 113,390,031.49 | 14,260,573.45 | 138,684,117.15 | 16,355,583.98 |
| 毛利率(%) | |||||
| 分部间抵销(%) | - | - | -71.38 | - | -34.79 |
| 医药制造业务(%) | - | - | 74.73 | - | 71.07 |
| 儿科(%) | - | 66.31 | - | 65.10 | - |
| 妇科(%) | - | 78.56 | - | 79.26 | - |
| 骨伤科(%) | - | 82.93 | - | 85.41 | - |
| 呼吸系统用药(%) | - | 76.46 | - | 72.45 | - |
| 抗感染(%) | - | 39.47 | - | 35.31 | - |
| 心脑血管(%) | - | 80.70 | - | 73.97 | - |
| 提供服务(%) | 11.68 | - | - | - | - |
| 销售商品(%) | 73.63 | - | - | - | - |
| 其他(%) | - | 47.30 | 23.04 | 48.84 | 25.80 |
| 收入构成(%) | |||||
| 分部间抵销(%) | - | - | -1.15 | - | -1.87 |
| 医药制造业务(%) | - | - | 94.14 | - | 94.24 |
| 儿科(%) | - | 10.70 | - | 11.99 | - |
| 妇科(%) | - | 4.76 | - | 5.89 | - |
| 骨伤科(%) | - | 22.47 | - | 22.87 | - |
| 呼吸系统用药(%) | - | 12.49 | - | 11.44 | - |
| 抗感染(%) | - | 4.54 | - | 5.22 | - |
| 心脑血管(%) | - | 31.03 | - | 24.50 | - |
| 提供服务(%) | 5.38 | - | - | - | - |
| 销售商品(%) | 94.62 | - | - | - | - |
| 其他(%) | - | 14.02 | 7.00 | 18.09 | 7.63 |
| 毛利构成(%) | |||||
| 分部间抵销(%) | - | - | 1.12 | - | 0.94 |
| 医药制造业务(%) | - | - | 96.66 | - | 96.24 |
| 儿科(%) | - | 9.79 | - | 11.30 | - |
| 妇科(%) | - | 5.16 | - | 6.75 | - |
| 骨伤科(%) | - | 25.71 | - | 28.27 | - |
| 呼吸系统用药(%) | - | 13.17 | - | 12.00 | - |
| 抗感染(%) | - | 2.48 | - | 2.67 | - |
| 心脑血管(%) | - | 34.55 | - | 26.23 | - |
| 提供服务(%) | 0.89 | - | - | - | - |
| 销售商品(%) | 99.11 | - | - | - | - |
| 其他(%) | - | 9.15 | 2.22 | 12.79 | 2.83 |